Shots:Viridian reported positive long-term durability data from the P-III (THRIVE) study evaluating 5 infusions of veligrotug (veli) or PBO (Q3W), with primary topline analysis at 15wks and follow-up to 52wks, in active thyroid eye disease (TED) pts. (N=30)Study demonstrated that 70% (21/30) were proptosis responders at 15wks. and maintained at least a 2…
